Biogen ends Parkinson's program due to lengthy timeline.
Biogen has discontinued a Phase III program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics, citing the study's complexity and long timeline. The study, dubbed LIGHTHOUSE, began in September and was slated for completion in 2031.